Sphingolipid, and dermatologic composition comprising same for external application
A novel sphingolipid is disclosed. The novel sphingolipid is in liquid form at room temperature due to a low melting point, and blends easily with a variety of vegetable and/or animal oils. A dermatologic composition for external application containing the novel sphingolipid is also disclosed. The composition is useful in providing anti-inflammatory protection, improving moisturization, protecting the skin from ultraviolet (UV) light, or enhancing skin barriers.
1. A sphingolipid represented by Chemical Formula 1:
wherein:
R 1 is CH 2 —CH 2 , CH═CH, or C(H) R 4 —CH 2 ;
R 2 is a saturated or unsaturated aliphatic hydrocarbon group of 12 to 28 carbon atoms;
R 3 is a saturated or unsaturated aliphatic hydrocarbon group of 12 to 28 carbon atoms substituted or unsubstituted with a hydroxyl group; and
a plurality of R 4 's are the same as or different from each other and are each independently an aliphatic acyl group of 1 to 6 carbon atoms or a hydroxyl (OH) group,
provided that at least one of the plurality of R 4 's contains at least an aliphatic acyl group of 1 to 6 carbon atoms.
2. The sphingolipid of claim 1 , wherein the sphingolipid represented by Chemical Formula 1 contains an acetyl (CH 3 CO—) group in at least one of the plurality of R 4 's.
3. The sphingolipid of claim 1 , wherein the sphingolipid is represented by any one of Chemical Formulas 2 to 7,
wherein in Chemical Formulas 2 to 7,
R 1 to R 3 are each defined as in claim 1 .
4. The sphingolipid of claim 1 , wherein R 3 of Chemical Formula 1 includes, as a raw material, an oil derived from at least one supply source of sea buckthorn, palm, sunflower, rapeseed, canola, olive, coconut, soybean, horse, cattle, sheep, bee, fish, crustacean, and human.
5. The sphingolipid of claim 1 , wherein the sphingolipid has a melting point (mp) of 40° C. or lower.
6. The sphingolipid of claim 1 , wherein the sphingolipid has solubility in at least one oil of plant oils, animal oils, fraction oils, and synthetic oils.
7. The sphingolipid of claim 1 , wherein in thin layer chromatography (TLC) using development solvents of chloroform:methanol: formic acid=190:15:1 (volume ratio), the Rf value of the sphingolipid is higher than the Rf value of an unacylated ceramide.
8. The sphingolipid of claim 1 , wherein the sphingolipid has a pH of 3 to 7.
9. A composition for external application to the skin comprising, as an active ingredient, the sphingolipid of claim 1 , a pharmaceutically acceptable salt thereof, or a solvate thereof.
10. The composition of claim 9 , wherein the composition is used for anti-inflammation, improving moisturization, or enhancing skin barriers.
11. The composition of claim 9 , wherein the composition is used for repairing skin damage induced by ultraviolet (UV) light or alleviating skin irritation.
12. The composition of claim 9 , wherein the composition is used for hair damage prevention, hair moisturization, lip moisturization, or lip protection.
13. The composition of claim 9 , wherein the sphingolipid is contained at an amount of 0.00001 to 50 wt % relative to the total weight of the composition.
14. The composition of claim 9 , wherein the composition further comprises at least one of phytosphingosine, sphingosine, and sphinganine.
15. The composition of claim 9 , wherein the composition further comprises at least one of ceramide 1 (EOS), ceramide 2 (NS), ceramide 3 (NP), ceramide 4 (EOH), ceramide 5 (AS), ceramide 6 (NH), ceramide 7 (AP), ceramide 8 (AH), and ceramide 9 (EOP).
16. The composition of claim 9 , wherein the composition is an oil formulation containing no emulsifier.
17. A pharmaceutical composition comprising, as an active ingredient, the sphingolipid of claim 1 , a pharmaceutically acceptable salt thereof, or a solvate thereof.
18. A cosmetic composition comprising, as an active ingredient, the sphingolipid of claim 1 , a pharmaceutically acceptable salt thereof, or a solvate thereof.
19. A quasi-drug composition comprising, as an active ingredient, the sphingolipid of claim 1 , a pharmaceutically acceptable salt thereof, or a solvate thereof.